Real possibilities of using Lactobacillus reuteri B-9448 in clinical practice: A modern approach to old problems (review)

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Considering the availability of a large selection of probiotics on the pharmaceutical market warrants that doctors know all the possible biological effects. Lactobacillus reuteri exerts antimicrobial action against pathogenic bacterial species, viruses, and fungi, as well as anti-inflammatory, immunomodulatory, detoxifying effects, acid resistance, and promotion of the restoration of intestinal microbiota. L. reuteri B-9448 is one of the most accessible and effective strains in the formulations of modern probiotics used for the prevention and correction of various conditions and diseases.

The biologically active additive Reuteri ECOlab, which combines the unique properties of living L. reuteri bacteria, highly active products of their metabolism, and MCT oil, allows the drug to be used in combination therapy of acute diarrhea in children and adults and rotavirus infections, Helicobacter pylori infections, antibiotic-associated diarrhea, functional abdominal pain, and allergic reactions in children. This probiotic can be administered in the form of drops, which makes it convenient, and the formulation is devoid of alcohols, emulsifiers, flavors, preservatives, and dyes, which makes it free of the risk of overdose and hence safe for use.

Full Text

Restricted Access

About the authors

Svetlana Yu. Tyukavkina

Rostov State Medical University

Email: galinagh@bk.ru
ORCID iD: 0000-0001-9291-2012
SPIN-code: 2796-8796

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Rostov-on-Don

Elvira L. Alutina

Rostov State Medical University

Email: galinagh@bk.ru
ORCID iD: 0000-0001-6968-0583
SPIN-code: 8657-9480

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Rostov-on-Don

Tatiana G. Suranova

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies, Academy of Postgraduate Education

Author for correspondence.
Email: suranovatatiana@mail.ru
ORCID iD: 0000-0003-3411-1027
SPIN-code: 7326-5273

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, 28 Orekhovy boulevard, Moscow, 115682

References

  1. Grumet L, Tromp Y. Stiegelbauer V. The development of high-quality multispecies probiotic formulations: From bench to market. Nutrients. 2020;12(8):2453. doi: 10.3390/nu12082453
  2. Kalyuzhin OV, Afanasev SS, Bykov AS. Oral probiotics as anti-infectious immune response stimulators in the respiratory tract. Ter Arkh. 2016;88(5):118-124. (In Russ). doi: 10.17116/terarkh2016885118-124
  3. Nikonov EL, Popovа EL. Microbiota. Moskow: Media Sfera; 2019. 255 р. (In Russ).
  4. Ivashkin VT, Mayev IV, Abdulganieva DI, et al. Practical recommendations of scientific society for the study of human microbiome and the russian gastroenterological association on use of probiotics, prebiotics, synbiotics and functional foods in treatment and prevention of gastroenterol ogical diseases in childrenand adults. Russ J Gastroenterol Hepatol Coloproctol. 2021;31(2):65–91. (In Russ). doi: 10.22416/1382-4376-2021-31-2-65-91
  5. Osipova IG, Evlashkina VF, Davydov DS, Sakanjan EI. General monographs on probiotics preparations for state pharmacopoeia of the Russian Federation ХIII edition first experience in the world pharmacopoeia practice. Int J Applied Fundamental Res. 2016;(6):272–276. (In Russ).
  6. Gavrilova NN, Ratnikova IA, Orazymbet SE. Breeding of active strains of probiotic bacteria with a wide spectrum of biological activity and antibiotic resistance. Int J Applied Fundamental Res. 2021;(7):12–16. (In Russ).
  7. Ploskireva AA. Probiotic therapy: from indications to choice. Russ Med J. 2018;26(2-2):100–101. (In Russ).
  8. Strandwitza P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693(Pt B):128–133. doi: 10.1016/j.brainres.2018.03.015
  9. Kaibysheva VO, Nikonov EL. Probiotics from the standpoint of evidence-based medicine. Russ J Evidence-Based Gastroenterol. 2019;8(3):45–54. (In Russ). doi: 10.17116/dokgastro2019803145
  10. Trick WE, Sokalski SJ, Johnson S, et al. Effectiveness of probiotic for primary prevention of Clostridium difficile infection: A single-center before-and-after quality improvement intervention at a tertiary-care medical center. Inf Control Hospital Epidemiol. 2018;39(7):765–770. doi: 10.1017/ice.2018.76
  11. Sniffen JC, McFarland LV, Evans CT, Goldstein EJ. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One. 2018;13(12):e0209205. doi: 10.1371/journal.pone.0209205
  12. Rondanelli M, Faliva MA, Perna S, et al, Castel-lazzi AM. Using probiotics in clinical practice: Where are we now? A review of existing metaanalyses. Gut Microbes. 2017;8(6):521–543. doi: 10.1080/19490976.2017.1345414
  13. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence (Background Document). Oxford Centre for Evidence-Based Medicine. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/explanation-of-the-2011-ocebm-levels-of-evidence. Accessed: 15.02.2023.
  14. Chervinets VM, Mironov AY, Chervinets YV, Bazlov SN. The state and role of esophagus, stomach, intestinal microbiota in patients with ulcer disease, chronic gastritis, esophagitis. Klinicheskaya laboratornaya diagnostika. 2019;65(1):42–49 (In Russ). doi: 10.18821/0869-2084-2020-65-1-42-49
  15. Kharseeva GG, Alieva AA, Sylka OI, et al. Adhesivity оf standard and biofilm cultures of toxigenic Corynebacterium diphtheriaе strains. Almanac Clin Med. 2017;45(2):154–158. (In Russ). doi: 10.18786/2072-0505-2017-45-2-154-158
  16. Zakharova IN, Berezhnaya IV, Klimov LY, et al. Probiotics in the management of respiratory diseases: Ways of interaction and therapeutic perspectives. Meditsinsky Sovet. 2019;(2):173–182. (In Russ). doi: 10.21518/2079-701X-2019-2-173-182
  17. Davydova MM. Microbiology, virology and immunology of the oral cavity: Textbook (2nd ed, revised and updated). Moscow: GEOTAR-Media; 2019. 720 p. (In Russ).
  18. Zverev VV, Boychenko MN. Medical microbiology, virology and immunology: Textbook on the discipline “Microbiology, virology and immunology” for students of institutions of higher professional education studying in the specialties 060101.65 “Medical care”, 060103.65 “Pediatrics”, 060104.65 “Medical and preventive care” in 2 volumes. Moscow: GEOTAR-Media; 2014. (In Russ).
  19. Chervynets YV, Chervynets VM, Shenderov BA. Modern ideas about the biotechnological potential of human symbiotic microbiota. Upper Volga Med J. 2018;17(1):19–26. (In Russ).
  20. Semenikhina VF, Rozhkova IV, Begunova AV, et al. Development of biotechnology of fermented milk product with Lactobacillus reuteri LR1 and the evaluation of its functional property in experiment in vitro and in vivo. Problems Nutrition. 2018;87(5):52–62. (In Russ). doi: 10.24411/0042-8833-2018-10053
  21. Kholodkov SV, Bezrodny SL, Kiseleva VA, Pomazanov VV. Technology for designing a biologically active supplemented based on Lactobacillus reuteri. News GSTU. Medicine, Pharmacy. 2021;(3):69–73. (In Russ).
  22. Chervinets VM, Chervinets YV, Petrova OA, et al. Gastrointestinal microbiota of the newborns of the first month of life of the Tver region. Klinicheskaya laboratornaya diagnostika. 2018;63(9):579–583 (In Russ). doi: 10.18821/0869-2084-2018-63-9-579-583
  23. Kornienko ЕА. Food allergies, intestinal microbiota and probiotics. Meditsinskiy Sovet. 2022;16(1):178–183. doi: 10.21518/2079-701X-2022-16-1-178-183
  24. Kharseeva GG, Tyukavkina SY. Fundamentals basics. Assessment of artificial active immunity (material for preparing the lecture). Inf Bolezni: Novosti Mneniya Obuchenie. 2020;9(3):106–118. (In Russ). doi: 10.33029/2305-3496-2020-9-3-106-118
  25. Gasretova TD, Tyukavkina SY, Kharseeva GG, Alutina EL. Streptococci. Microbiological diagnostics of streptococcal infections: Textbook. Rostov-on-Don; 2016. 72 р. (In Russ).
  26. Alieva AA, Kharseyeva G, Labushkina AV, et al. Ability of biofilm model and cultures toxigenic strains Corynebacterium diphtheriae to adhesion and invasion. Problems Med Mycology. 2017;19(2):32. (In Russ).
  27. Zakharova IN, Berezhnaya IV, Sugyan NG, et al. What do we know today about Lactobacillus reuteri? Med Council. 2018;(2):163–169. (In Russ). doi: 10.21518/2079-701X-2018-2-163-169
  28. Kiňová HS, Bilková A. Isolation and identification of new lactobacilli from goatling stomach and investigation of reuterin production in Lactobacillus reuteri strains. Folia Microbiologica. 2013;58(1):33–38. doi: 10.1007/s12223-012-0166-x
  29. Spinler JK, Sontakke A, Hollister E, et al. From prediction to function using evolutionary genomics: Human-specific ecotypes of Lactobacillus reuterihave diverse probiotic functions. Genome Biol Evolution. 2014;6(7):1772–1789. doi: 10.1093/gbe/evu137
  30. Castiblanco GA, Yucel-Lindberg T, Roos S, Twetman S. Effect of lactobacillus reuteri on cell viability and PGE2 production in human gingival fibroblasts. Probiotics Antimicrobial Proteins. 2017;9(3): 278–283. doi: 10.1007/s12602-016-9246-6
  31. Pandey SP, Bender MJ, Meisel M. Systemic immunoregulatory consequences of gut commensal translocation AC McPherson. Trends Immunol. 2021;42(2):137–150. doi: 10.1016/j.it.2020.12.005
  32. Luo M, Hu M, Feng X, et al. Preventive effect of Lactobacillus reuteri on melanoma. Biomed Pharmacother. 2020;(126):109929. doi: 10.1016/j.biopha.2020.109929
  33. Popova EN, Orlova AS, Ponomarev AB, et al. The possibilities of using probiotics in the anti-aging aspect. Microbiota. Moscow: Media Sfera; 2019. 256 p. (In Russ).
  34. Komarova ON. Efficacy of Lactobacillus reuteri in clinical practice. Russ Med J. 2021;4(3):277–283. (In Russ). doi: 10.32364/2618-8430-2021-4-3-277-283
  35. Gong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: A meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;(8):6530–6543.
  36. Chervinets YV, Chervinets VM, Mironov AY. Symbiotic relationship betweeen lactobacilli and microorganisms of the gastrointestinal tract. Tver: Tverskoy gosudarstvennoy meditsinskoy akademii; 2016. 214 р. (In Russ).
  37. Chervinets VM, Chervinets YV, Leonteva AV, et al. The microbiome of oral cavity patients with periodontitis, adhesive and biofilm forming properties. Klinicheskaya laboratornaya diagnostika. 2021;66(1): 45–51. (In Russ.). doi: 10.18821/0869-2084-2021-66-1-45-51
  38. Ho SN, Acharya A, Sidharthan S, et al. A Systematic review and meta-analysis of clinical, immunological, and microbiological shift in periodontitis after nonsurgical periodontal therapy with adjunctive use of probiotics. J Evid Based Dent Pract. 2020;20(1):101397. doi: 10.1016/j.jebdp.2020.101397
  39. Ang LY, Too HK, Tan EL, et al. Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines. Virol J. 2016;(13):111. doi: 10.1186/s12985-016-0567-6
  40. Nikolaeva SV, Kanner EV, Shushakova EK, Ploskireva AA. One strain of L. reuteri: Many possibilities. Topical issues of application in pediatrics. Russ Med J. 2022;5(1):72–77. doi: 10.32364/2618-8430-2022-5-1-72-77
  41. Rusu E, Enache G, Cursaru R, et al. Prebiotics and probiotics in atopic dermatitis (Review). Exp Ther Med. 2019;18(2):926–931. doi: 10.3892/etm.2019.7678

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Biological effects of Lactobacillus reuteri strain.

Download (430KB)
Indexing metadata
3. Fig. 2. The use of Lactobacillus reuteri for the prevention and correction of various conditions and diseases.

Download (450KB)
Indexing metadata

Copyright (c) 2023 Eco-vector

License URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 014448 от 08.02.1996. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80652 от 15.03.2021 .


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies